Product Development and Clinical Trials - The lead product candidate, abdakibart (AVTX-009), is currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS) with topline data expected in Q2 2026[20]. - The LOTUS trial involves approximately 250 adults with moderate to severe HS, evaluating two dosing regimens of abdakibart (AVTX-009) against placebo over a 16-week treatment phase[23]. - The company completed enrollment in the Phase 2 LOTUS trial in October 2025 and expects to report topline data in Q2 2026[22]. - The company plans to explore further indication expansion for abdakibart (AVTX-009) following the Phase 2 trial results[24]. - The first patient was enrolled in the global Phase 2 LOTUS clinical trial for abdakibart (AVTX-009) in October 2024, and enrollment was completed in October 2025[145]. - The company faces risks related to the clinical development of abdakibart (AVTX-009), including potential delays and additional costs that could adversely affect financial condition[148]. - Delays in clinical testing may increase product development costs and harm the business, potentially shortening exclusive commercialization rights[157]. - Factors causing delays include failure to obtain FDA authorization, issues with trial design, and difficulties in patient recruitment[158]. - Challenges in enrolling and retaining subjects in clinical trials may delay timelines and increase costs[160]. - The company is conducting clinical trials for abdakibart (AVTX-009) in foreign jurisdictions, with the FDA's acceptance of data from these trials being subject to specific conditions[209]. Market Potential and Competition - The global HS market is projected to exceed $10 billion by 2035, with an estimated 3.4 million people in the U.S. affected by HS in 2024, rising to 3.5 million by 2035[30]. - Only about 1.0 million of the estimated 3.4 million HS patients in the U.S. were diagnosed and treated in 2024, with projections increasing to 1.6 million by 2035[30]. - The company is one of three with novel, non-biosimilar antibodies targeting IL-1β in clinical development, alongside Sunshine Guojian and TavoTek[48]. - Six additional companies are in phase 3 development programs for HS with various inhibitors, including IL-17 and JAK inhibitors[49]. - Competition in the inflammatory disease market includes major players like AbbVie, Lilly, Merck, and Novartis, which may have greater experience and resources[50]. - The company faces significant competition from established therapies and may struggle to secure market share[182]. - Market acceptance of product candidates is crucial for commercial success, and inadequate acceptance could hinder revenue generation[183]. Financial Condition and Funding - As of December 31, 2025, the company had $98.3 million in cash and cash equivalents and short-term investments, with current liabilities of $12.9 million[122]. - The company incurred a net loss of $78.3 million for the year ended December 31, 2025, with an accumulated deficit of $448.5 million[133]. - The company expects to require additional capital in the future to fund operations and advance product candidates, which may not be available on acceptable terms[122]. - The company plans to finance operations through equity offerings, debt financings, collaborations, and licensing arrangements, but lacks committed sources of external financing[123]. - The company has not generated any revenue from product sales and has not yet demonstrated the ability to obtain regulatory approvals or commercialize products[132]. - The company expects research and development expenses to increase substantially as it advances product candidates through clinical trials[122]. - The company may need to seek additional funds sooner than anticipated due to unforeseen expenses or delays in clinical trials[134]. - The company has not yet achieved profitability and may never do so, which could adversely affect its ability to raise capital and expand operations[126]. - The company’s future funding requirements will depend on various factors, including the successful completion of clinical development and regulatory approval[135]. Regulatory Environment - The FDA approval process is complex and may require extensive clinical trials, including Phase 1, Phase 2, and Phase 3 studies[51]. - Regulatory approval processes in foreign countries are independent of FDA approval and may require additional clinical data[55]. - The preparation of a New Drug Application (NDA) or Biologics License Application (BLA) requires substantial funds and resources, including user fees[69]. - The FDA may issue a Complete Response Letter (CRL) if the NDA or BLA does not meet regulatory criteria, requiring additional studies or information[70]. - Post-approval trials may be mandated by the FDA to gain further experience with the product in the intended therapeutic indication[65]. - The company must comply with extensive regulations governing the research, development, and marketing of biological products[58]. - The FDA has 10 months to complete its initial review of a Biologics License Application (BLA) after filing, or 6 months for priority reviews[75]. - Approval of a BLA requires compliance with current Good Manufacturing Practices (cGMP) and may necessitate a Risk Evaluation and Mitigation Strategy (REMS)[76]. - A complete response letter from the FDA indicates that the BLA will not be approved in its current form and may require additional clinical data or trials[77]. - The FDA's approval process can be delayed by requests for additional information, which may limit or prevent regulatory approval[78]. - Post-approval, drugs are subject to ongoing FDA regulation, including requirements for recordkeeping and reporting adverse experiences[79]. - The company may incur substantial costs related to regulatory compliance and post-marketing obligations if product candidates are approved[195]. - Changes in regulatory policies or government guidance could hinder marketing approval and increase compliance costs[201]. - The company’s ability to conduct clinical trials and obtain approvals may be affected by external factors such as funding shortages and changes in leadership at regulatory agencies[202]. Legal and Compliance Risks - The company is subject to increased scrutiny from federal and state enforcement bodies regarding interactions with healthcare providers, which may lead to investigations and settlements[94]. - The company faces potential legal and regulatory actions for non-compliance with healthcare laws, which could result in significant penalties, including fines and operational restrictions[96]. - Compliance with healthcare laws, including the Anti-Kickback Statute, is essential to avoid significant penalties and ensure lawful operations[92]. - Legislative changes, such as the Inflation Reduction Act of 2022, may impact the company's financial liability and pricing strategies, including reducing out-of-pocket spending caps for Medicare beneficiaries from $7,050 to $2,000 starting in 2025[100]. - The company must navigate complex pricing metrics and reporting requirements imposed by federal price reporting laws, which could affect revenue[95]. - The company is subject to the Biologics Price Competition and Innovation Act, which establishes a 12-year exclusivity period for reference biological products before biosimilars can be approved[108]. - The company may face challenges in the biosimilar approval pathway due to the complexity of biological products and manufacturing processes[107]. - The company is subject to strict anti-corruption and trade laws, with potential serious consequences for violations, especially as it increases activities outside the U.S.[216]. Pricing and Reimbursement Challenges - Coverage and reimbursement from third-party payors are critical for the commercial success of approved products, with significant uncertainty regarding availability[81]. - The lack of uniform coverage policies among third-party payors complicates the reimbursement process, requiring extensive data submission[83]. - Legislative efforts to control drug pricing may lead to downward pressure on prices and affect profitability[90]. - In foreign markets, pricing approval may be required before marketing, with varying requirements across countries[91]. - The implementation of the Global Benchmark for Efficient Drug Pricing Model (GLOBE) and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) model may require the company to pay incremental rebates based on international benchmark prices[103]. - The company is affected by the 2% reduction in Medicare payments to providers, which remains in effect through 2031, potentially impacting revenue streams[99]. - Pricing of prescription pharmaceuticals in foreign countries is often subject to governmental control, which may adversely affect the company's revenues[217]. - Current and future healthcare legislative reforms may materially impact the company's ability to profitably sell its product candidates[218].

Financial Performance - Cash, cash equivalents, and short-term investments were approximately $98.3 million as of December 31, 2025, expected to fund operations into 2028[6] - Research and development expenses increased to $50.1 million for the year ended December 31, 2025, up from $24.4 million in 2024, driven by the LOTUS trial[6] - General and administrative expenses rose to $22.9 million for the year ended December 31, 2025, an increase of $5.7 million from 2024[7] - Net loss for the year ended December 31, 2025, was $78.3 million, compared to a net loss of $35.1 million in 2024[7] - Basic and diluted net loss per share was $5.84 for the year ended December 31, 2025, compared to $7.94 in 2024[9] - Total revenues for 2025 were $59,000, a decrease from $441,000 in 2024[9] - Total operating expenses for 2025 were $72.98 million, compared to $68.95 million in 2024[9] - Total assets decreased to $116.5 million as of December 31, 2025, from $150.7 million in 2024[8] - Total stockholders' equity decreased to $83.0 million as of December 31, 2025, from $133.0 million in 2024[8] Clinical Trials and Development - Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is expected in Q2 2026[5] - The company is focused on the growth and strategy related to its clinical trials for abdakibart (AVTX-009) and other future product candidates[15] - Avalo is conducting the Phase 2 LOTUS trial, with expectations for clinical data readouts to be announced in the future[15] Risk Management - Avalo's management emphasizes that forward-looking statements are based on various assumptions and are subject to significant risks and uncertainties[15] - The company is assessing its anticipated operating expenses and cash runway to ensure sufficient funding for its operations[15] - Avalo acknowledges potential risks including drug development costs, trial timing, regulatory risks, and reliance on key personnel[15]

Project Interests and Operations - The Company holds a 44.8% interest in the Cauchari-Olaroz lithium brine project, co-owned with Ganfeng Lithium Co., Ltd., which holds a 46.7% interest[27]. - Cauchari-Olaroz reached an average production rate of around 85% of its nameplate capacity of 40,000 tpa lithium carbonate during 2025[30]. - The Company is advancing expansion plans for Cauchari-Olaroz, considering an additional capacity of 45,000 tpa of Lithium Carbonate Equivalent (LCE)[30]. - Cauchari-Olaroz is currently producing technical grade lithium carbonate and is not equipped to produce battery-grade lithium carbonate, which involves additional complexities[31]. - The Company retained a 44.8% interest in the Cauchari-Olaroz project and a majority interest in the Pastos Grandes Project following the Separation Transaction on October 3, 2023[130]. - The provincial government of Jujuy, where Cauchari-Olaroz is located, has taken an 8.5% equity interest in the project, fulfilling an obligation to contribute to the province's development[92]. - The Cauchari-Olaroz project has measured mineral resources of 2,742,686 tons of lithium and 14,599,317 tons of lithium carbonate equivalent (LCE) as of December 31, 2025[179]. - Proven mineral reserves at Cauchari-Olaroz are estimated at 75,315 tons of lithium and 400,886 tons of LCE as of December 31, 2025[180]. - The Cauchari-Olaroz Operation's production capacity is planned to increase from 25,000 tonnes per annum (tpa) to 40,000 tpa of lithium carbonate, with a feasibility study authorized for this expansion[194]. - The Company produced approximately 6,000 tonnes of lithium carbonate in 2023, with a target of achieving commercial production of approximately 25,400 tonnes in 2024[203]. Financial Position and Risks - As of December 31, 2025, the Company had indebtedness under its equity-settleable Convertible Notes with a carrying value of $234.2 million and a face value of $258.8 million, maturing on January 15, 2027[63]. - Exar's outstanding third-party debt, including accrued interest, amounted to $292.7 million as of December 31, 2025, with a cash balance of $86.7 million, resulting in third-party net debt of $206.0 million[65]. - The Company requires additional financing to support the development, construction, expansion, and operation of its projects, which may lead to increased leverage and financial risks[78]. - The Company has a history of negative cash flow and its ability to continue as a going concern depends on generating sufficient cash flows from lithium carbonate production or securing additional financing[81]. - The Company is subject to currency fluctuations, particularly between the Argentine peso and U.S. dollar, which may significantly affect cash flows[105]. - Current Argentine exchange controls restrict access to foreign currency, potentially impacting the Company's ability to meet financial obligations[107]. - The Company may face increased regulatory reporting requirements if it loses its status as a "Foreign Private Issuer," leading to higher compliance costs[111]. Market Conditions and Pricing - The price of lithium carbonate is subject to substantial volatility, influenced by global supply and demand dynamics[117]. - The Company expects that lithium carbonate prices will continue to be affected by the business strategies of major producers and global economic conditions[119]. - The lithium market has experienced significant price volatility, with prices declining since 2022 due to increased supply and slower-than-anticipated growth in electric vehicle demand[147]. - There is uncertainty regarding the long-term growth of the lithium market and potential technological substitutions that could negatively impact the Company[121]. Regulatory and Operational Challenges - The development of the Pastos Grandes (PPG) project is subject to significant risks, including the need for successful negotiation of a joint venture and uncertainties in mineral deposit viability[36][37]. - The operating environment in Argentina remains sensitive to inflation and foreign exchange volatility, which could adversely affect operating costs and project timelines[41]. - The Company is subject to various regulatory risks, including changes in tax laws and environmental regulations, which could affect its operations and profitability[91]. - The Company faces heightened regulatory oversight due to geopolitical competition and government policy towards critical minerals, which may disrupt its business operations[94]. - Compliance with evolving environmental regulations could increase operational costs and adversely affect the Company's financial condition[96]. - Legal proceedings related to environmental and climate change matters may arise, which could divert management's attention and incur substantial costs[109]. Strategic Partnerships and Acquisitions - The Company completed the acquisition of Millennial Lithium on January 25, 2022, making it a wholly owned subsidiary[129]. - On April 20, 2023, the Company acquired all common shares of Arena Minerals, which also became a wholly owned subsidiary[129]. - Ganfeng acquired $70 million in newly issued shares of PGCo, representing a 14.9% interest, with proceeds allocated to advancing lithium projects in Argentina[131]. - Ganfeng increased its participating interest in Exar to 51% through a $16 million capital contribution, while the Company retained a 49% interest[195]. - JEMSE acquired an 8.5% participating interest in Exar for a consideration of $1 plus 8.5% of capital contributions, with future contributions requiring loans from GFL and the Company[196]. Operational Efficiency and Community Engagement - The Company has implemented workforce development and training initiatives to strengthen local capabilities, but persistent labor shortages could materially affect operations[49]. - The Company has implemented comprehensive health and safety measures to comply with regulations, but failure to maintain these standards could harm its reputation and operations[50]. - The Company is focused on efficient operations, water conservation, and strong partnerships with local communities[183]. - The Company has signed contracts with local aboriginal communities for surface rights, supporting local infrastructure and education programs[201]. Technical and Geological Insights - The average lithium concentration in brine pumped from Cauchari-Olaroz is 588.26 mg/L[180]. - The Cauchari brine has a total dissolved solids (TDS) concentration of approximately 27%, indicating a high saturation of sodium chloride[207]. - A total of 4,176 meters of Reverse Circulation drilling was conducted from September 2009 to August 2010, providing valuable geological and hydrogeological data[210]. - The Company has conducted various exploration programs, including seismic and gravity surveys, to evaluate the lithium development potential of the Cauchari-Olaroz Operation area[209]. - The Mineral Resource Estimate for the Cauchari-Olaroz Operation was completed using a new Leapfrog Geo model, incorporating hydrostratigraphic units based on the salar lithistratigraphic units[220]. - The prior Mineral Resource estimate from 2024 was prepared in accordance with S-K 1300 and has been filed under NI 43-101 standards[218]. - Pumping tests were conducted at eleven locations from 2011 to 2019 to estimate aquifer parameters related to brine recovery[217]. - The Mineral Resource and Mineral Reserve estimates were reviewed and confirmed by Dr. Mark King, a qualified person under S-K 1300[219].

Financial Performance - Revenue from gold sales increased to $42,406,253 in 2025, up 64.4% from $25,765,373 in 2024[302]. - Gross profit for 2025 was $26,205,927, representing a gross margin of 61.8%, compared to $12,950,493 and a margin of 50.3% in 2024[302]. - Net income attributable to Idaho Strategic Resources, Inc. reached $16,715,674 in 2025, compared to $8,836,685 in 2024, marking an increase of 89.5%[303]. - For the year ended December 31, 2025, the Company reported a net income of $16,631,198, compared to $8,753,377 for the year ended December 31, 2024, representing an increase of 89.5%[331]. - The diluted net income per share for 2025 was $1.14, up from $0.67 in 2024, indicating a significant increase of 70.1%[331]. Assets and Investments - Total current assets increased to $51,346,719 in 2025 from $11,742,073 in 2024, representing a growth of approximately 337%[299]. - Total assets reached $116,238,730 in 2025, a substantial increase from $44,021,630 in 2024, representing a growth of approximately 164%[300]. - Investment in US treasury notes increased to $27,679,881 in 2025 from $7,775,193 in 2024, reflecting a growth of approximately 256%[299]. - The investment in equity securities was recorded at $4,129,521 in 2025, indicating a new addition as there were no such investments in 2024[299]. - As of December 31, 2025, the total fair value of investments in US treasury notes is $55,973,000, with an amortized cost of $55,331,724, reflecting unrealized gains of $795,818 and unrealized losses of $154,542[399]. - The total investments in equity securities and mutual funds as of December 31, 2025, amount to $8,087,018, with an amortized cost of $7,976,926, showing unrealized gains of $205,756 and unrealized losses of $95,664[402]. Liabilities and Equity - Total current liabilities rose to $3,677,583 in 2025, a 61.5% increase from $2,279,549 in 2024[301]. - Total liabilities increased to $5,396,782 in 2025, a 49.4% rise from $3,608,316 in 2024[301]. - Stockholders' equity grew to $110,841,948 in 2025, compared to $40,413,314 in 2024, reflecting a 174.5% increase[301]. Cash Flow and Investments - Cash flows from operating activities were $19,101,691 in 2025, up from $10,840,886 in 2024, indicating a 76.5% increase[307]. - The company invested $61,458,139 in net cash used by investing activities in 2025, compared to $20,762,889 in 2024[307]. Inventory and Sales - Gold sales receivable grew to $3,912,922 in 2025, up from $1,578,694 in 2024, indicating an increase of about 148%[299]. - The company reported a total deferred tax asset of $2,351,700 as of December 31, 2025, down from $4,533,600 in 2024[382]. - Total sales for the year ended December 31, 2025, amounted to $42,406,253, a significant increase from $25,765,373 in 2024, with concentrate sales to H&H accounting for 98% of gold sales[396]. Operational Highlights - The company maintains a strategic presence in the U.S. Critical Minerals sector, focusing on rare earth elements (REE) projects[311]. - The Company operates as a single segment, with all financial information presented on a consolidated basis, assessed by the Chief Operating Decision Maker[353]. - The company has no critical audit matters reported for the current period, indicating stable financial reporting practices[296]. Stock and Compensation - The company granted 400,000 stock options to employees on January 15, 2025, with an exercise price of $11.50, resulting in a stock-based compensation expense of $1,505,244 for the current year[389]. - The intrinsic value of outstanding stock options as of December 31, 2025, was approximately $9,486,000, with a weighted average remaining term of 2.04 years[389]. Tax Matters - The total income tax provision for the year ended December 31, 2025, was $426,100, with a current income tax provision of $334,400[380][381]. - The company recognized a deferred income tax provision of $91,700 for the year ended December 31, 2025, with significant components including federal and state taxes[381].

Revenue and Business Model - Wellgistics Health's revenue is now derived from pharmaceutical dispensing, care management services, SaaS fees, and product procurement and distribution following the Wood Sage and Wellgistics acquisitions [272]. - The company serves over 5,000 registered pharmacies nationwide, providing competitive pricing and unique products, with a product portfolio consisting of 65% topical generics, 20% oral generics, 10% brand formulations, and 5% over-the-counter products [266]. - Wellgistics Health's pharmacy network services 1.3 billion prescriptions annually, representing a $47 billion market at wholesale cost [274]. - The company aims to expand its service coverage area and strengthen clinical expertise in key therapeutic categories, while also enhancing its digital health tools to improve patient outcomes [274]. - Wellgistics Health's business model focuses on the specialty lite therapy area, with therapies priced between $500 and $3,000, which may be impacted by inflationary pressures [279]. Market Overview - The U.S. market for medicines reached $435 billion in 2023, with specialty drugs accounting for over 50% of prescription drug spending despite representing less than 10% of total drugs [273]. - The company has established over 60 manufacturing relationships to enhance market access and visibility for its clients [266]. Financial Performance - For the year ended December 31, 2025, net revenues were $23,337,860, an increase of 28.5% from $18,128,831 in 2024, primarily due to acquisitions [288][289]. - Cost of revenues for 2025 totaled $29,764,279, up 82.5% from $16,361,517 in 2024, driven by full-year costs from acquired subsidiaries and liquidity constraints [290]. - Gross profit for 2025 was a loss of $(6,426,419), compared to a profit of $1,767,314 in 2024, resulting in a gross margin decline to (27.5)% from 9.7% [291]. - General and administrative expenses surged to $70,332,827 in 2025 from $6,797,782 in 2024, largely due to $54,048,525 in non-cash stock-based compensation [293][294]. - The company recognized a non-cash impairment charge of $12,554,266 for goodwill and intangible assets in 2025, reflecting a decline in estimated fair value [298][300]. - Other expenses, net for 2025 were $7,525,433, a significant increase from $711,094 in 2024, primarily due to higher interest expenses and losses on debt extinguishment [302]. - Interest expense for 2025 was $4,579,556, compared to $831,467 in 2024, reflecting higher outstanding debt balances [303]. - The Company recognized a net loss of $101,274,530 for the year ended December 31, 2025, contributing to net cash used in operating activities of $10,855,029 [335]. Cash Flow and Financing - The company expects to generate positive cash flow from operations in 2025 due to annual revenue from Wood Sage and Wellgistics LLC, but may need additional funds for strategic initiatives [305]. - Short-term liquidity needs include expanding facilities and upgrading equipment, while long-term needs focus on strategic acquisitions and investments in technology [306]. - Net cash provided by financing activities for the year ended December 31, 2025, was $10,750,790, compared to $1,782,893 in 2024 [334]. - Cash inflows during the financing activities were partially offset by $23,957,337 in repayments of the revolving line of credit [340]. - The Company entered into a new credit agreement for a line of credit of $10,000,000, with an outstanding balance of $1,643,923 as of December 31, 2025 [330]. - The Company issued a promissory note in the principal amount of $17,500,000, with a non-cash loss on debt extinguishment of $1,353,663 recognized during the year ended December 31, 2025 [322]. Accounting and Reporting - The Company recognizes revenue at the point of sale, with the majority of orders placed via its website [346]. - Revenue for Wellgistics LLC is recognized when goods are delivered to the customer, subject to various deductions [347]. - The Company accounts for acquisitions as business combinations, allocating the purchase price to the acquired assets and liabilities based on their estimated fair values [352]. - The Company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [353].

IPO and Financing - The company completed its Initial Public Offering (IPO) on May 12, 2025, raising gross proceeds of $150,000,000 from the sale of 15,000,000 Public Units at $10.00 per Unit[22]. - A private sale of 500,000 Private Placement Units was completed simultaneously with the IPO, generating an additional $5,000,000 in gross proceeds[23]. - The total amount of $150,000,000 from the IPO and Private Placement was placed in a Trust Account[24]. - The company incurred total fees of $9,567,513 related to the IPO, including a cash underwriting fee of $3,000,000 and a deferred fee of $6,000,000[212]. - Cash held outside the Trust Account as of December 31, 2025, was $777,703, primarily used for evaluating target businesses and due diligence[216]. - An affiliate of the Sponsor provided a loan of up to $300,000 under the IPO Promissory Note, with $108,352 fully repaid upon the IPO completion on May 12, 2025[218]. - The company may receive Working Capital Loans up to $1,500,000, convertible into units of the post-Business Combination entity at $10.00 per unit, with no borrowings under such loans as of December 31, 2025[219]. Business Combination Plans - The company must complete its initial Business Combination by May 12, 2027, or face termination and distribution of Trust Account amounts[25]. - The Hecate Business Combination was unanimously approved by the Board of Directors and includes provisions for significant asset contributions and share conversions[28]. - The Business Combination is expected to close in the third quarter of 2026, pending shareholder approvals and customary closing conditions[39]. - The company aims to identify and complete its initial Business Combination with a company focused on providing reliable power solutions and improving sustainability[62]. - The company has established criteria for evaluating business combination candidates, focusing on those that exhibit unrecognized value and have attractive growth opportunities[75]. - The company may pursue an initial Business Combination in any business or industry, including financially unstable or early-stage companies[95]. - The company may seek Business Combination opportunities in industries outside of its management's expertise if the current target, Hecate, is not consummated[172]. Shareholder Considerations - Shareholder approval will be sought for the Hecate Business Combination, as required by applicable law or stock exchange rules[112]. - Public Shareholders will have the opportunity to redeem their shares either through a general meeting or a tender offer, at the company's discretion[128]. - To approve the initial Business Combination, approximately 32.7% (4,900,001 shares) or 55.4% (8,316,667 shares) of the 15,000,000 Public Shares must be voted in favor, depending on the resolution type[133]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[140]. - If the initial Business Combination is not completed, Public Shareholders who elected to redeem their shares will not be entitled to redeem for their pro rata share of the Trust Account[145]. Financial Performance and Projections - The company generated net income of $3,373,817 for the period from January 9, 2025, through December 31, 2025, primarily from interest earned on marketable securities held in the Trust Account[211]. - The company has not generated any operating revenues to date and expects to incur increased expenses as a public company[210]. - The company has approximately $153,867,836 available for a Business Combination as of December 31, 2025, excluding amounts held outside the Trust Account for working capital[94]. - The expected Redemption Price upon dissolution is approximately $10.26 per Public Share as of December 31, 2025, but actual amounts may be lower due to creditor claims[151]. Risks and Challenges - The company may experience significant dilution for public shareholders due to the conversion of founder shares and potential additional equity issuances[78]. - The company may face conflicts of interest among its officers and directors when evaluating potential Business Combination opportunities[86]. - The company may face challenges in completing its initial Business Combination, including potential litigation and the need for additional financing, which could compel it to restructure or abandon the Business Combination[169]. - There is substantial doubt about the company's ability to continue as a "going concern" due to potential financing needs and the deadline for liquidating the Trust Account[183]. - The company may face increased competition for attractive Business Combination targets as the number of SPACs evaluating targets rises, potentially increasing costs[169]. Management and Strategy - The Management Team has extensive experience in negotiating and completing Business Combinations, including with Volta and Hyliion[56]. - The company has a strategy to optimize acquired businesses through the expertise and networks of its Board of Directors[54]. - The management team believes that their network of industry contacts provides a competitive advantage in sourcing attractive business combination targets[68]. - The management team has a deep understanding of capital markets, which is crucial for evaluating and executing business combination transactions[70]. - The management team may face conflicts of interest due to their commitments to other businesses, which could negatively impact the Business Combination process[177].

IPO and Fundraising - The company completed its Initial Public Offering (IPO) on May 12, 2025, raising gross proceeds of $150 million from the sale of 15,000,000 Public Units at $10.00 per Unit[22]. - A total of $5 million was generated from the private sale of 500,000 Private Placement Units, with the Sponsor purchasing 350,000 Units and the Representatives purchasing 150,000 Units[23]. - The company has placed $150 million from the IPO and Private Placement into a Trust Account maintained by Continental[24]. - The company incurred total fees of $9,567,513 related to the IPO, including a cash underwriting fee of $3,000,000 and a deferred fee of $6,000,000[212]. - The company has not generated any operating revenues to date and expects to incur increased expenses as a result of being a public company[210]. Business Combination Plans - The company must complete its initial Business Combination by May 12, 2027, or face termination and distribution of Trust Account amounts[25]. - The Hecate Business Combination was unanimously approved by the Board of Directors and includes provisions for the conversion of shares and assets[28]. - The Business Combination is expected to close in the third quarter of 2026, pending shareholder approvals and customary closing conditions[39]. - The company aims to complete its initial Business Combination with a company focused on expanding reliable power availability and improving sustainability[62]. - The company may seek to extend the Combination Period, requiring shareholder approval, which could affect its Nasdaq listing[26]. Financial Provisions and Conditions - The Hecate BCA stipulates that the aggregate transaction proceeds from the Trust Account must be at least $50 million after redemptions and expenses[32]. - If cash proceeds at Closing from the Trust Account equal $50 million or more, 80% of the At-Risk Shares will vest; otherwise, no shares will vest[45]. - The Tax Receivable Agreement mandates the company to pay 85% of net tax benefits realized from increases in tax basis related to exchanges of Parent Hecate Units for EGH Class A Common Stock[41]. - The company may need to seek additional financing if the cash portion of the purchase price exceeds the amount available from the Trust Account, net of redemptions by Public Shareholders[98]. - The Nasdaq Rules require that the company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account[89]. Management and Strategy - The Management Team has extensive experience in negotiating and completing Business Combinations, including with Volta and Hyliion[56]. - The company’s acquisition strategy focuses on companies that provide solutions for reliable power, emissions reduction, and sustainability[62]. - The management team has extensive operational experience and public company expertise, which is expected to enhance the strategic vision and operational performance of acquired businesses[66]. - The management team believes their network of industry contacts provides a competitive advantage in sourcing attractive business combination targets[68]. - The company aims to identify scalable businesses that can benefit from strategic insights and capital to accelerate growth, particularly in clean and renewable energy sectors[64]. Risks and Challenges - The company acknowledges potential dilution for public shareholders due to the conversion of founder shares and other securities[78]. - The company may face challenges in completing its initial Business Combination, including potential litigation and the need for additional financing, which could compel it to restructure or abandon the Business Combination[169]. - The company has substantial doubt about its ability to continue as a "going concern" due to potential financing needs and the deadline for liquidating its Trust Account[183]. - The company may face increased competition for attractive Business Combination targets as the number of SPACs evaluating targets rises[169]. - The company may engage in Business Combinations with private companies about which little information is available, increasing the risk of acquiring less profitable targets[169]. Shareholder Matters - Shareholder approval will be sought for the Hecate Business Combination, as required by applicable law or stock exchange rules[112]. - Public Shareholders will have the opportunity to redeem their shares either through a general meeting or a tender offer, at the company's discretion[128]. - To approve the initial Business Combination, approximately 32.7% (4,900,001 shares) or 55.4% (8,316,667 shares) of the 15,000,000 Public Shares must be voted in favor, depending on the resolution type[133]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[140]. - If the initial Business Combination is not completed, Public Shareholders who elected to redeem their shares will not be entitled to redeem for their pro rata share of the Trust Account[145]. Operational and Financial Status - The company generated net income of $3,373,817 for the period from January 9, 2025, through December 31, 2025, primarily from interest earned on marketable securities held in the Trust Account[211]. - As of December 31, 2025, the Trust Account held approximately $153,867,836 in marketable securities, including $3,867,836 of interest income[215]. - Cash held outside the Trust Account as of December 31, 2025, was $777,703, primarily used for evaluating target businesses and due diligence[216]. - The company may use the balance of cash released from the Trust Account for general corporate purposes after the initial Business Combination[96]. - The expected Redemption Price upon dissolution is approximately $10.26 per Public Share as of December 31, 2025, but actual amounts may be lower due to creditor claims[151].

Financial Overview - Vendome Acquisition Corporation I completed its initial public offering of 20,000,000 Units at an offering price of $10.00 per Unit, generating gross proceeds of $200,000,000 [289]. - A total of $200,000,000 of the net proceeds from the initial public offering and private placement was placed in a trust account [290]. - For the period from January 28, 2025, through December 31, 2025, the company reported a net income of $3,870,407, primarily from investment income of $4,032,946 [293]. - Cash used in operating activities for the same period was $787,011, with net change in operating assets and liabilities of $624,472 [297]. - As of December 31, 2025, cash held in the trust account amounted to $204,032,946, intended for the initial business combination [299]. - The company incurred transaction costs of $2,105,782 related to the initial public offering, including a cash underwriting fee of $1,000,000 [296]. - Cash provided by financing activities for the period was $201,091,587, primarily from the initial public offering and private placement [298]. Debt and Financing - The company has no long-term debt or off-balance sheet financing arrangements as of December 31, 2025 [303][304]. - The company intends to use funds held outside the trust account primarily for identifying and evaluating target businesses [300]. - The company may need additional financing to complete its initial business combination or to redeem public shares if necessary [302].

Financial Compliance and Reporting - The Company refiled its management's discussion and analysis for the financial year ended December 31, 2023, and the interim period ended June 30, 2024, following a review by the Alberta Securities Commission[314]. - The Company received a notification from Nasdaq regarding non-compliance with the Minimum Bid Requirement, with a 180-day period to regain compliance[326]. Fundraising and Financial Activities - The Company closed a registered direct offering and concurrent private placement, raising gross proceeds of US$1,499,993 through the sale of 810,810 Common Shares and pre-funded warrants[317]. - The Company announced a non-brokered private placement raising US$925,000 through the issuance of 1,267,123 units at a price of US$0.73 per unit[330]. - The Company closed a registered direct offering for 1,750,000 Common Shares at a purchase price of US$0.63 per share, raising gross proceeds of US$1,102,500[336]. - The cost of preparing and submitting a New Drug Application (NDA) is substantial, currently over US$4.6 million for an NDA with clinical information[446]. Product Development and Pipeline - The Company launched a precision medicine program targeting kidney disease, combining genetic diagnostics and XO inhibition[316]. - The Company announced a new late-stage program, XRx-026, aimed at treating gout for individuals intolerant to allopurinol[320]. - The Company is approximately 12 months from filing a New Drug Application (NDA) for the XRx-026 program, targeting an estimated US$700 million annual market opportunity[331]. - The lead product candidate, XRx-026, aims to treat gout and is expected to generate peak net sales revenue exceeding US$500 million annually[356]. - The XRx-008 program targets ADPKD and is preparing for a Phase 3 registration clinical trial, with potential for accelerated approval based on FDA discussions[355]. - The company has a pipeline of four product candidates: XRx-026, XRx-008, XRx-101, and XRx-225, addressing various unmet medical needs[354]. - XRx-225 is in non-clinical development stages, with plans to advance to Phase 1 clinical testing, pending discussions with the FDA[416]. Clinical Trials and Regulatory Approval - The anticipated clinical development of XORLOTM includes a proposed two-part bridging clinical study to support FDA approval, focusing on pharmacokinetics and therapeutic equivalence to allopurinol[391]. - The FDA seeks to review applications for standard review drug products within ten months and priority review drugs within six months[448]. - The FDA may issue a Complete Response Letter (CRL) indicating deficiencies in the NDA, which could require additional clinical trials or labeling changes[450]. - The FDA may require post-approval testing and surveillance to monitor the drug's safety or efficacy[451]. - Phase 1 clinical trials focus on safety in healthy volunteers, while Phase 2 evaluates efficacy and safety in a limited patient population[443]. Market and Competitive Landscape - The company faces significant uncertainty regarding coverage and reimbursement for its product candidates, which may affect sales and profitability[495]. - The pharmaceutical industry is experiencing pricing pressures due to managed healthcare trends and legislative proposals, impacting the company's ability to maintain price levels[496]. - The Inflation Reduction Act of 2022 introduces drug pricing reforms that could reduce the prices and reimbursement rates for the company's products, adversely affecting profitability[502]. - The competitive landscape includes major pharmaceutical companies with greater resources, posing challenges for the company's product candidates[428]. Intellectual Property and Compliance - XORTX holds patents for proprietary formulations of xanthine oxidase inhibitors, with three patents granted and additional applications submitted[360]. - The patent portfolio includes five active patent families, with ongoing efforts to secure and maintain patent protection for product candidates[420]. - The company aims to expand its intellectual property holdings through in-licensing of new technologies and compositions[417]. - The company monitors emerging intellectual property that may impact its business and takes appropriate actions when necessary[418]. Healthcare Regulations and Compliance - The company must navigate complex data privacy laws, including HIPAA and state-specific regulations, to avoid penalties and ensure compliance[481]. - The company is subject to various anti-corruption laws, which prohibit improper payments to government officials and can lead to liability for third-party actions[480]. - Non-compliance with FDA regulations can lead to significant consequences, including product recalls, fines, and withdrawal of product approvals[477]. - Potential violations of federal and state laws could result in significant civil, criminal, and administrative penalties, including monetary fines and loss of eligibility for FDA approvals[511].

Product Development and Innovation - SINTX Technologies received FDA 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025, marking its entry into reconstructive foot and ankle surgery in the U.S.[28] - The company is advancing AI-designed 3D printing capabilities for custom medical implants, integrating silicon nitride with PEEK to enhance biocompatibility and reduce infection risks[39]. - The company is developing new products with antipathogenic properties, including a patent for "Antipathogenic Fibrous Materials" granted in 2025[49]. - The company is focused on expanding its product portfolio across orthopedic, extremity, and other medical applications, including the commercialization of the SiNAPTIC® foot and ankle wedge system[149]. - The company is developing a range of innovative products, including intervertebral fusion devices, hip implants, and implants with improved antibacterial characteristics[89]. Manufacturing and Quality Control - SINTX's manufacturing facility in Salt Lake City is FDA registered and ISO certified, ensuring high-quality production of silicon nitride products[31]. - The company operates a 19,000 square foot manufacturing facility in Salt Lake City, Utah, certified under ISO 13485:2016 for medical devices, allowing full control over the manufacturing process[48]. - The company operates a 30,764 square foot manufacturing facility certified under ISO 13485 and FDA quality systems regulations[145]. Financial Performance and Position - As of December 31, 2025, the company had cash and cash equivalents of $4.1 million and an accumulated deficit of $292.1 million[126][132]. - The company incurred a net loss of $10.4 million for the year ended December 31, 2025, compared to a net loss of $11.0 million for the previous year[132]. - The company has an At The Market Offering Agreement with an aggregate offering price of $6.4 million, with $6.0 million available capacity under the ATM[126]. - The company has incurred substantial losses primarily due to sales and marketing, research and development, and general administrative expenses[132]. - The company acknowledges that prolonged negative economic conditions could adversely affect its financial position and liquidity[170]. Regulatory Compliance and Challenges - Regulatory compliance is critical, with the FDA requiring either 510(k) clearance or PMA approval for new medical devices, which can be a lengthy and complex process[93][97]. - The PMA process requires extensive data to demonstrate safety and effectiveness, and can take several years to complete, with no guarantee of approval[97]. - The transition to the EU MDR has increased regulatory scrutiny and compliance costs, impacting the company's ability to market products in the EU[102][103]. - The company must navigate international regulatory requirements, which vary by jurisdiction and may impose additional testing and documentation burdens[101][106]. - The company is subject to federal and state healthcare laws, including the Anti-Kickback Statute and the False Claims Act, which impose significant compliance obligations[109][111][112]. Market and Competitive Landscape - The orthopedic market is highly competitive, with major players like Medtronic and Johnson & Johnson dominating the market[140]. - The company faces competition from major players in the medical device market, including Medtronic, Johnson & Johnson, Stryker, and Zimmer Biomet, which have greater financial and manufacturing resources[88][91]. - The demand for personalized implants is increasing, and SINTX is well-positioned to meet this need with its innovative solutions tailored to individual patient anatomy[40]. Risks and Uncertainties - The company faces substantial risks in product development and commercialization, including potential delays, increased costs, and regulatory obstacles that could adversely affect revenue and growth prospects[151]. - The company may face delays in product development and commercialization if adequate funding is not secured[126][127]. - Changes in reimbursement policies and coverage determinations may adversely affect hospital purchasing decisions and utilization of the company's products[119][122]. - The company is vulnerable to cybersecurity threats that could disrupt operations and compromise confidential information, potentially leading to financial loss and reputational harm[177]. - The company is subject to evolving data privacy and cybersecurity regulations, which may increase costs and expose it to regulatory investigations and liabilities[178]. Intellectual Property and Legal Matters - The company holds twenty-one issued U.S. patents and ten issued foreign patents, with the last of these patents expiring in 2042[55]. - The company lacks patent protection for the composition of matter for its solid silicon nitride, allowing competitors to create similar formulations[214]. - The medical devices industry is characterized by extensive litigation over intellectual property rights, which could consume substantial resources[221]. - Product liability claims could exceed insurance coverage, significantly harming the company's financial condition[223]. - The company relies on a combination of patent protection and trade secret laws to protect its proprietary technology, which may not be sufficient[208]. Research and Development - The company invests substantial amounts in research and development to pursue advancements in a wide range of technologies, products, and services[181]. - The company has received three NIH grants to develop 3D printed silicon nitride/polymer implantable medical devices[48]. Strategic Partnerships and Collaborations - The company is establishing OEM partnerships to replace existing materials with silicon nitride, which may expose it to risks related to profitability and compliance with strict standards[160]. - The company has entered into agreements with orthopedic surgeons for product development, which may lead to disputes over ownership rights[217].